Literature DB >> 34242114

The demand for a COVID-19 vaccine in Kenya.

Carlos E Carpio1, Oscar Sarasty1, Darren Hudson1, Anthony Macharia2, Mumina Shibia3.   

Abstract

The goal of achieving herd immunity to the coronavirus requires high vaccination acceptance levels on the part of the population. The objectives of this study were to: 1) Measure individuals' willingness to pay (WTP) for a COVID-19 vaccine in Kenya; 2) evaluate the effect of vaccine characteristics (duration of protection and efficacy) and individuals' socioeconomic variables on WTP, and 3) estimate the aggregate demand and economic value of a COVID-19 vaccine. The contingent valuation (CV) method was used as the basis for the analyses. Data for this study were obtained from a survey of 1,050 individuals in Kenya conducted from April 7 to April 15, 2020. The survey included CV questions using a double-bounded dichotomous choice format. Results reveal that most of the individuals in Kenya (at least 96%) were willing to accept a COVID-19 vaccine. Approximately 80% of individuals were willing to pay a positive amount. Conservative estimates of individuals' mean WTP for the vaccine range from USD 49.81 to USD 68.25 (depending on vaccine characteristics). Both vaccine duration of protection and efficacy were found to influence WTP (p < .10). The perceived probability of being hospitalized, age, gender, education, location and region of residence, and household income were also found to be associated with WTP for the vaccine (p < .10). In conclusion, the COVID-19 vaccine is highly valued and accepted by the Kenyan population; however, a high percent of the population is unwilling to pay for it or is only willing to pay a low price.

Entities:  

Keywords:  Africa; COVID-19; SARS-C0V-2; vaccine acceptance; vaccine attributes; willingness to pay

Mesh:

Substances:

Year:  2021        PMID: 34242114      PMCID: PMC8437500          DOI: 10.1080/21645515.2021.1938494

Source DB:  PubMed          Journal:  Hum Vaccin Immunother        ISSN: 2164-5515            Impact factor:   4.526


  23 in total

1.  Interim estimates of 2013/14 influenza clinical severity and vaccine effectiveness in the prevention of laboratory-confirmed influenza-related hospitalisation, Canada, February 2014.

Authors:  Sa McNeil; V Shinde; M Andrew; Tf Hatchette; J Leblanc; A Ambrose; G Boivin; Wr Bowie; F Diaz-Mitoma; M Elsherif; K Green; F Haguinet; S Halperin; B Ibarguchi; K Katz; J Langley; P Lagace-Wiens; B Light; M Loeb; J McElhaney; D Mackinnon-Cameron; Ae McCarthy; M Poirier; J Powis; D Richardson; M Semret; S Smith; D Smyth; G Stiver; S Trottier; L Valiquette; D Webster; L Ye; A McGeer
Journal:  Euro Surveill       Date:  2014-03-06

2.  Conjoint analysis of French and German parents' willingness to pay for meningococcal vaccine.

Authors:  David Bishai; Roger Brice; Isabelle Girod; Aneta Saleh; Jenifer Ehreth
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

3.  Planning for a COVID-19 Vaccination Program.

Authors:  Sarah Schaffer DeRoo; Natalie J Pudalov; Linda Y Fu
Journal:  JAMA       Date:  2020-06-23       Impact factor: 56.272

4.  The use of the health belief model to assess predictors of intent to receive the COVID-19 vaccine and willingness to pay.

Authors:  Li Ping Wong; Haridah Alias; Pooi-Fong Wong; Hai Yen Lee; Sazaly AbuBakar
Journal:  Hum Vaccin Immunother       Date:  2020-07-30       Impact factor: 3.452

5.  Willingness-to-pay for a COVID-19 vaccine and its associated determinants in Indonesia.

Authors:  Harapan Harapan; Abram L Wagner; Amanda Yufika; Wira Winardi; Samsul Anwar; Alex Kurniawan Gan; Abdul M Setiawan; Yogambigai Rajamoorthy; Hizir Sofyan; Trung Quang Vo; Panji Fortuna Hadisoemarto; Ruth Müller; David A Groneberg; Mudatsir Mudatsir
Journal:  Hum Vaccin Immunother       Date:  2020-09-29       Impact factor: 3.452

6.  The marginal willingness-to-pay for attributes of a hypothetical HIV vaccine.

Authors:  Michael P Cameron; Peter A Newman; Surachet Roungprakhon; Riccardo Scarpa
Journal:  Vaccine       Date:  2013-06-05       Impact factor: 3.641

7.  Contingent assessment of the COVID-19 vaccine.

Authors:  Leidy Y García; Arcadio A Cerda
Journal:  Vaccine       Date:  2020-06-25       Impact factor: 3.641

8.  The demand for a COVID-19 vaccine in Ecuador.

Authors:  Oscar Sarasty; Carlos E Carpio; Darren Hudson; Patricia A Guerrero-Ochoa; Ivan Borja
Journal:  Vaccine       Date:  2020-11-06       Impact factor: 3.641

9.  Willingness to pay and financing preferences for COVID-19 vaccination in China.

Authors:  Jiahao Wang; Yun Lyu; Haijun Zhang; Rize Jing; Xiaozhen Lai; Huangyufei Feng; Maria Deloria Knoll; Hai Fang
Journal:  Vaccine       Date:  2021-02-27       Impact factor: 3.641

10.  Willingness to Pay for a COVID-19 Vaccine.

Authors:  Arcadio A Cerda; Leidy Y García
Journal:  Appl Health Econ Health Policy       Date:  2021-02-23       Impact factor: 2.561

View more
  10 in total

1.  On willingness to pay for Covid-19 vaccines: a case study from India.

Authors:  Upasak Das; Udayan Rathore; Rupayan Pal
Journal:  Hum Vaccin Immunother       Date:  2021-11-10       Impact factor: 3.452

Review 2.  COVID-19 vaccine hesitancy in Africa: a scoping review.

Authors:  Betty B B Ackah; Michael Woo; Lisa Stallwood; Zahra A Fazal; Arnold Okpani; Ugochinyere Vivian Ukah; Prince A Adu
Journal:  Glob Health Res Policy       Date:  2022-07-19

Review 3.  Covid-19 Vaccine Acceptance and Determinant Factors among General Public in East Africa: A Systematic Review and Meta-Analysis.

Authors:  Astawus Alemayehu; Abebaw Demissie; Mohammed Yusuf; Abebe Gemechu Lencha; Lemessa Oljira
Journal:  Health Serv Res Manag Epidemiol       Date:  2022-06-13

4.  Financing COVID-19 vaccination in sub-Saharan Africa: lessons from a nation-wide willingness to pay (WTP) survey in Ghana.

Authors:  Robert Kaba Alhassan; Edward Nketiah-Amponsah; Mustapha Immurana; Aaron Asibi Abuosi
Journal:  BMC Public Health       Date:  2022-06-30       Impact factor: 4.135

5.  COVID-19 Vaccine Demand and Financial Incentives.

Authors:  Carlos E Carpio; Ioana A Coman; Oscar Sarasty; Manuel García
Journal:  Appl Health Econ Health Policy       Date:  2021-10-05       Impact factor: 3.686

Review 6.  Application of bioreactor technology for cell culture-based viral vaccine production: Present status and future prospects.

Authors:  Zhongbiao Fang; Jingting Lyu; Jianhua Li; Chaonan Li; Yuxuan Zhang; Yikai Guo; Ying Wang; Yanjun Zhang; Keda Chen
Journal:  Front Bioeng Biotechnol       Date:  2022-08-09

7.  Black People Narrate Inequalities in Healthcare Systems that Hinder COVID-19 Vaccination: Evidence from the USA and the UK.

Authors:  Ifeanyichukwu Anthony Ogueji; Benie McDenisa Demoko Ceccaldi; Maia Makeda Okoloba; May Maloba; Adebayo O Adejumo; Olabanjo O Ogunsola
Journal:  J Afr Am Stud (New Brunsw)       Date:  2022-10-11

8.  Willingness to pay for and willingness to vaccinate with the COVID-19 vaccine booster dose in China.

Authors:  Hui Jun Zhou; Lei Pan; Hui Shi; Ji Wei Luo; Pei Wang; Hannah K Porter; Ye Bi; Minghui Li
Journal:  Front Pharmacol       Date:  2022-09-20       Impact factor: 5.988

9.  Predictors of COVID-19 Vaccine Hesitancy in South African Local Communities: The VaxScenes Study.

Authors:  Patrick D M C Katoto; Saahier Parker; Nancy Coulson; Nirvana Pillay; Sara Cooper; Anelisa Jaca; Edison Mavundza; Gregory Houston; Candice Groenewald; Zaynab Essack; Jane Simmonds; Londiwe Deborah Shandu; Marilyn Couch; Nonkululeko Khuzwayo; Nobukhosi Ncube; Phelele Bhengu; Heidi van Rooyen; Charles Shey Wiysonge
Journal:  Vaccines (Basel)       Date:  2022-02-25

Review 10.  COVID-19 Vaccine Acceptance among Low- and Lower-Middle-Income Countries: A Rapid Systematic Review and Meta-Analysis.

Authors:  Muhammad Mainuddin Patwary; Md Ashraful Alam; Mondira Bardhan; Asma Safia Disha; Md Zahidul Haque; Sharif Mutasim Billah; Md Pervez Kabir; Matthew H E M Browning; Md Mizanur Rahman; Ali Davod Parsa; Russell Kabir
Journal:  Vaccines (Basel)       Date:  2022-03-11
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.